Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech Inc (SNES) provides innovative fertility control solutions for sustainable rodent management through its EPA-registered products. This news hub offers investors and pest control professionals timely updates on corporate developments and scientific advancements in humane pest control technology.
Access official press releases covering product launches, regulatory milestones, and partnership announcements. Our curated collection includes updates on ContraPest deployments, Evolve soft bait applications, and research breakthroughs in integrated pest management strategies.
Discover updates organized by key operational areas: regulatory approvals, distribution expansions, and scientific validation studies. Stay informed about developments in non-lethal pest control solutions that align with global sustainability initiatives and changing environmental regulations.
Bookmark this page for direct access to SenesTech's verified announcements. Monitor progress in biotechnology applications for urban pest management and ecological preservation through our comprehensive news repository.
SenesTech (NASDAQ: SNES), the manufacturer of EPA-registered rodent birth control products, reported strong Q2 2025 financial results. The company achieved record revenue of $625,000, up 36% year-over-year, with Evolve™ Rodent Birth Control products growing 94% and representing 83% of total revenue.
Key highlights include record gross profit margin of 65.4%, improved from 54.2% in Q2 2024, and a net loss of $1.6 million. The company maintains a strong cash position of $11.2 million as of August 5, 2025, providing runway through 2027. SenesTech expanded its municipal pilot deployments across major U.S. cities and completed a move to a new automated manufacturing facility in July 2025.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has closed a warrant exercise transaction generating $6.3 million in gross proceeds. The transaction involved the exercise of existing warrants for 1,458,872 shares at $4.15 per share, with H.C. Wainwright acting as exclusive placement agent.
As part of the deal, SenesTech issued new unregistered short-term warrants to purchase 2,188,308 shares at $5.25 per share, with a purchase price of $0.125 per warrant. These new warrants, if fully exercised, could generate additional proceeds of $11.5 million. The company plans to use the net proceeds for working capital and general corporate purposes.
[ "Secured $6.3 million in immediate gross proceeds from warrant exercise", "Potential additional proceeds of $11.5 million if new warrants are fully exercised", "New warrants priced at $5.25, representing a 26.5% premium to previous warrant exercise price" ]SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $6.3 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares at $4.15 per share.
As part of the deal, the company will issue new unregistered short-term warrants for 2,188,308 shares at an exercise price of $5.25 per share, with a purchase price of $0.125 per warrant. These new warrants will expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate additional proceeds of $11.5 million.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has scheduled its Second Quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close.
The company will host a conference call at 5:00 p.m. Eastern time on the same day to discuss the results. Investors can access the live webcast through the company's Investor Relations website, with a replay available for 90 days following the presentation.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced the closing of a warrant exercise transaction that generated $4.4 million in gross proceeds. The transaction involved the exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share.
As part of the transaction, the company issued new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate approximately $6.0 million in additional gross proceeds. H.C. Wainwright served as the exclusive placement agent for the transaction.
The company plans to use the net proceeds for working capital and general corporate purposes.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $4.4 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share, with an expected closing date of July 1, 2025.
As part of the transaction, SenesTech will issue new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants will be exercisable immediately and expire fifteen months after the effective date of the resale registration statement. If fully exercised, these new warrants could generate additional gross proceeds of approximately $6.0 million.
The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright is serving as the exclusive placement agent for the transaction.
SenesTech (NASDAQ: SNES) has reported successful results from major urban deployments of its Evolve™ Rat Birth Control solution in Hong Kong and San Francisco. The company's innovative approach combines fertility control with traditional rodenticide methods, demonstrating significant effectiveness in urban pest control.
In Hong Kong's high-density mixed-use building deployment, the company achieved dramatic reduction in rodent sightings and bait consumption within three months. Similar success was recorded in San Francisco, with notable decreases in rodent activity and new births. SenesTech is now preparing for a container-sized order from Hong Kong following these positive results.
SenesTech (NASDAQ: SNES) has successfully completed a nine-month field trial of Evolve™ Rat Birth Control at UC Irvine's University Hills residential community. The trial, conducted with Irvine Campus Housing Authority (ICHA), demonstrated 98% bait consumption across 267 stations, replacing traditional rodenticides with an eco-friendly solution.
The initiative, which began in September 2024, was driven by resident pressure to adopt safer pest management practices. The project supported the HOOT Group's efforts to promote owl nesting and reduce rodenticide use. Following the successful trial, ICHA is placing a multi-pallet restocking order for continued deployment and expansion.